Sukumar Nagendran, President and Head of R&D at Taysha Gene Therapies, Inc. (TSHA), sold 740,344 shares at $4.75 ($3.4M) on 2025-11-28, disclosed to the SEC on 2025-12-01.
Open-market sale of $3.4M TSHA by President and Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.75 | 110,125 | $523K | 15.4% |
| 2 | $4.75 | 110,125 | $523K | 15.4% |
| 3 | $4.51 | 260,047 | $1.2M | 34.6% |
| 4 | $4.51 | 260,047 | $1.2M | 34.6% |
| Total | $4.58 avg | 740,344 | $3.4M | 100% |
| Filing → |
| TSHA | SELL | 2026-01-27 | $547K | — | Filing → |
| TSHA | SELL | 2026-01-14 | $942K | — | Filing → |
| TSHA | SELL | 2025-09-12 | $646K | — | Filing → |